Burden of heart failure Care
- Gheorghiade M et al. Am J Cardiol. 2005;96:11-17
- Gheorghiade M et al. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes. Academics’, clinicians’, industry’s, regulators’, and payers’ perspectives. Heart Failure Clin. 2013.9;285-290.
- Marti NC et al.Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail. 2013;6:1095-1101
- O’Connor CM et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduce left ventricular ejection fraction: results from efficacy of vasopressin antagonism in heart failure outcome stuy with tolvaptan (EVEREST) program. Am Heart J. 2010;159:841-849.e1.
- Krumholz HM. Post-hospital Syndrome – An acquired, Transient Condition of Generalized Risk . NEJM. 2013;368;2
- Marti NC et al. Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail. 2013;6:1095-1101
- Metra M et al. Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation. 2010;122:1782-1785.
- Gheorghiade M et al. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes. Academics’, clinicians’, industry’s, regulators’, and payers’ perspectives. Heart Failure Clin. 2013:9;285-290
- Yancy C et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240-e327.
- Psotka MA, Teerlink JR. Strategies to Prevent Postdischarge Adverse Events Among Hospitalized Patients with Heart Failure. Heart Failure Clin. 2013;9:303-320.
- Ryan J et al. Change in Readmissions and Follow-up Visits as Part of a Heart Failure Readmission Quality Improvement Initiative. Am J Med. 2013 Nov;126(11):989-994.e1. doi: 10.1016/j.amjmed.2013.06.027. Epub 2013 Sep 18.
- Bradley EH et al. Hospital strategies associated with 30-day readmission rates for patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(4):444-450.
- Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J published 20 May 2016, 10.1093/eurheartj/ehw128
- Habal MV et al. Association of Heart Rate at Hospital Discharge with Mortality and Hospitalizations in Patients with Heart Failure. Circ Heart Fail. 2014 Jan 1;7(1):12-20
- Greene JC et al. EVEREST Trial Investigators. The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm: Insights From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) Trial. JACC Heart Failure. 2013;1(6):488-496.
Optimize Heart Failure Care
- Saldarriaga CI, Gonzalez G, Navarrete S, Echeverria LE, Novoa M, Murrillo N, Rivera A, Rodriguez MJ, Rolong B, Trout G, Martinez C, Arguello CV, Semanche L, Contreras E, Vanegas J [ESC]
Economic impact of ivabradine use in the vulnerable phase: results from the ROCI registry.
European Journal of Heart Failure (2018) 20 (Suppl. S1) 5–638 : P281.
- Do Thi Nam P, Ha Ngoc B, Do Van D, Do Quang H, Cowie MR [ESC]
Effect of the Optimize Heart Failure Care (OHF) Program on clinic and patients outcomes at Ho Chi Minh City (HCMC) Heart Institute, Vietnam.
Journal of Heart Failure (2018) 20 (Suppl. S1) 5–638 : P399.
- Dadashova GM, Farajova NZ [ESC]
Ivabradine in the treatment of heart failure with reduced ejection fraction.
Journal of Heart Failure (2018) 20 (Suppl. S1) 5–638 : P955.
- Grebennikova A, Lopatin Y, Sisakian H, Hayrapetyan H, Pagava Z, Glezer M, Chesnikova A, Abdullaev T, Dadashova G, Tarlovskaya E, Kurlianskaya A, Berkinbaev S, Rakisheva A, Voronkov L, Kipiani Z [ESC]
Discharge heart rate and clinical outcomes in patients with atrial fibrillation and decompensated heart failure: data from the Optimize Heart Failure Care Program.
Journal of Heart Failure (2018) 20 (Suppl. S1) 5–638 : P1123.
- Reyes EE, Punzalan FER, Reganit PFM, Agbayani MJF [ESC]
Trends in the performance measures of drug therapy for heart failure with reduced ejection fraction under the Optimize Heart Failure Care Program.
Journal of Heart Failure (2018) 20 (Suppl. S1) 5–638 : P1865.
- Lopatin YM, Grebennikova A, Sisakian H, Hayrapetyan H, Pagava Z, Abdullaev T, Dadashova G, Berkinbayev S, Rakisheva A, Chesnikova A, Tarlovskaya E, Kipiani Z, Koziolova N, Tseluyko V, Voronkov L [ESC]
Impact of physicians’ adherence to guideline-recommended therapy on heart failure re-hospitalizations: data from the Optimize Heart Failure Care Program.
Journal of Heart Failure (2018) 20 (Suppl. S1) 5–638 : P1537.
- Lopatin YM, Cowie MR, Grebennikova AA, Sisakian HS, Pagava ZM, Hayrapetyan HG, Abdullaev TA, Voronkov LG, Chesnikova AI, Tseluyko VI, Tarlovskaya EI, Dadashova GM, Berkinbaev SF, Glezer MG, Koziolova NA, Rakisheva AG, Kipiani ZV, Kurlyanskaya AK [IJC]
Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program.
Int J Cardiol. 2018 Jun 1;260:113-117.
- Stewart Coats AJ. [IJC]
Heart rate as a target: Ready for pole position? Int J Cardiol. 2018 Jun 1;260:131-132.
- Cowie MR, Lopatin YM, Saldarriaga C, Fonseca C, Sim D, Magaña JA, Albuquerque D, Trivi M, Moncada G, González Castillo BA, Sánchez MOS, Chung E [PubMed]
The Optimize Heart Failure Care Program: Initial lessons from global implementation Int J Cardiol. 2017;236:340-344.
- Eugenio B. Reyes, Jong-Won Ha, Isman Firdaus, Azmee Mohd Ghazi, Arintaya Phrommintikul, David Sim, Quynh NgaVu, Chung Wah Siu, Wei-Hsian Yin, Martin R. Cowie [ScienceDirect]
Heart failure across Asia: Same healthcare burden but differences in organization of care Int J Cardiol. 2016;223:163-167.
- Lopatin Y, Grebennikova A, Sisakian H, Hayrapetyan H, Pagava Z, Glezer M, Chesnikova A, Abdullaev T, Dadashova G, Tarlovskaya E, Kurlianskaya A, Koziolova N, Berkinbaev S, Rakisheva A, Voronkov L, Tseluyko V, Kipiani Z [Circulation]
Benefits of early co-administration of beta-blockers and ivabradine in patients hospitalized due to worsening heart failure: insights from a prospective pragmatic study within the Optimize Heart Failure Care Program Circulation 2017;136(Suppl.1):A12310.
- Saldarriaga CI, Gonzalez G, Navarrete S, Echeverria LE, Novoa M, Murillo N, Rivera A, Rodriguez MJ, Rolong B, Trout G, Martinez C, Arguello CV, Semanche L, Contreras E, Vanegas J [ESC]
Improving heart failure care in hospitals with and without a multidiscipinary heart failure program: results from optimize Colombia project Eur J Heart Fail. 2017;19(Suppl.S1):63.
- Schwartzmann P, Moreira HT, Mourilhe-Rocha R, Villacorta H, Souza-Neto JD, Sickler-Cruz T, Albuquerque D, Simoes MV [ESC]
Optimize Brazil – Analysis of a multidisciplinary approach in a multicenter Brazilian cohort to optimize heart failure treatment Eur J Heart Fail. 2017;19(Suppl.S1):73.
- Mircheva L, Yotov YY, Bocheva YB. Ivabradine and heart failure: experience from a real practice [ESC] Eur J Heart Fail. 2017; 19(Suppl. 1):406
- Sisakian H, Hayrapetyan H, Sahakyan L, Hovhanisyan M, Petrosyan H [ESC]
Ivabradine reduces rehospitalization in patients with chronic systolic heart failure: single country data from OPTIMIZE- HF Program Eur J Heart Fail. 2017;19( Suppl.S1 ):59.
- Lopatin Y, Grebennikova A, Sisakyan H, Hayrapetyan H, Dadashova G, Kurliandskaya A, Pagava Z, Kipiani Z, Berkinbayev S, Glezer M, Chesnikova A, Tarlovskaya E, Voronkov L, Tseluyko V, Abdullaev T [ESC]
Guidelines-recommended medications for heart failure in eight post-soviet countries: insights from the Optimize Heart Failure Care Program Eur J Heart Fail. 2017;19( Suppl.S1):224.
- Saldarriaga C I, Gonzalez G, Navarrete S, Echeverria LE, Novoa M, Murillo N, Rivera A, Rodriguez MJ, Rolong B, Trout G, Martinez C, Arguello CV, Semanche L, Contreras E, Vanegas J [ESC]
Effect of ivabradine in the vulnerable phase: results from de Optimize Colombia Project Eur J Heart Fail. 2017;19(Suppl.S1):231.
- Lopatin Y, Grebennikova A, Sisakian H, Hayrapetyan H, Pagava Z, Abdullaev T, Voronkov L, Tseluyko V, Chesnikova A, Glezer M, Koziolova N, Dadashova G, Berkinbaev S, Rakisheva A, Kurliandskaya A [ESC]
Beneficial effects of beta-blockers and ivabradine combination in patients hospitalized due to worsening of heart failure: findings from Optimize Heart Failure Care Program Eur J Heart Fail. 2017;19(Suppl.S1):288.
- Sisakian H, Hayrapetyan H, Sahakyan L, Hovhanisyan M, Petrosyan H [ESC]
Chronic systolic heart failure rehospitalization rates study from OPTIMIZE HF Program: data from two centers Eur J Heart Fail. 2017;19(Suppl.S1):244.
- Dadashova G. [ESC]
Characteristics, treatments, and outcomes of patients hospitalized for heart failure: a report from the OPTIMIZE-HF Registry (Azerbaijan) Eur J Heart Fail. 2017;19(Suppl.S1):404.
- Kurlianskaya AK, Denicevich TL [ESC]
Management of patients with chronic heart failure and mid-range left ventricular ejection fraction Eur J Heart Fail. 2017;19(Suppl.S1):557.
- Saldarriaga CI, Gonzalez G, Navarrete S, Echeverria LE, Novoa M, Murillo N, Rivera A, Rodriguez MJ, Rolong B, Trout G [Global Heart]
Optimization of heart failure treatment at hospital discharge: a 30-day follow-up study on behalf of the Roci Pilot Project Global Heart. 2016;11(Suppl. 2):e87.
- Do Thi Nam P, Do Quanh H, Cowie MR, et al.
Effect of the Optimize Heart Failure Care Program on clinical and patient outcomes – The pilot implementation in Vietnam. Int J Cardiol Heart Vasc. 2019; 22:169-173.
- Mourilhe-Rocha R, Pimenta de Melo Spineti P, Schwartzmann P, et al.
A multicenter Brazilian cohort to optimize heart failure treatment using an organized multidisciplinary approach – Optimize Brazil Eur J Heurt Fail. 2019; 21 (Suppl. S1): 62–P318
- Do Thi Nam P, Do Quang H, Ha Ngoc B, et al.
The optimize-heart failure care program in our heart institute in Vietnam Eur J Heurt Fail. 2019; 21 (Suppl. S1): 242–P1028
- LopatinYM, Grebennikova A , Sisakian H, et al.
The impact of patients adherence to the lifestyle advice on all-cause mortality in patients with heart failure: data from the Optimize Heart Failure Care Program Eur J Heurt Fail. 2019; 21 (Suppl. S1): 341–P1342
- Yotov Y, Mircheva L.
Benefits of early administration of ivabradine in stabilized patients hospitalized due to worsening heart failure: insights from the Optimize Heart Failure Care Program” Eur J Heurt Fail. 2019; 21 (Suppl. S1): 408–P1654
- Magana-Serrano JA , Cigarroa-Lopez JA , Cantero-Colin R, et al.
OPTIMIZE Heart Failure Care Program in Mexico. Impact on early and midterm Heart Failure readmissions. Eur J Heurt Fail. 2019; 21 (Suppl. S1): 525–P2042
- Saldarriaga CI.
Survival free of events during the “vulnerable phase” of heart failure: data from Optimize Colombia program. Eur J Heurt Fail. 2019; 21 (Suppl. S1): 444–P1767
